PAR-23-131: Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $225,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 17, 2024.
From the official notice on Grants.gov, last changed November 18, 2024. Checked November 7, 2026.
- Award ceiling$225,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsOptional
- Funded byNICHD, NIAID
- Median yearly award$235,125
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-23-131 were run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 7 projects) and National Institute of Allergy and Infectious Diseases (NIAID, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-131 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-111 | November 18, 2024 | Closed July 6, 2026 | Closed |
Key dates
| Posted | March 1, 2023 |
|---|---|
| Deadline | November 17, 2024 |
| Archived by Grants.gov | December 17, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $235,125; it allows up to $225,000 per award.
- Most of the money in the 3 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.
Funded under PAR-23-131 so far
NIH funded 9 projects under PAR-23-131 in fiscal 2024 to 2025, at 9 institutions. The median yearly award was $235,125.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-131 still open?
No. It closed on November 17, 2024.
Who can apply for Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)?
Closed November 17, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $225,000 each.
Who has been funded under PAR-23-131?
NIH RePORTER lists 9 projects funded under PAR-23-131 in fiscal 2024 to 2025, at 9 institutions. The most were at Icahn School of Medicine at Mount Sinai, Neurosant Therapeutics LLC, University of Texas HLTH Sci Ctr Houston.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)